Zusammenfassung
Acute respiratory distress syndrome is characterized by damage to the lung caused by various insults, including ventilation itself, and tidal hyperinflation can lead to ventilator induced lung injury (VILI). We investigated the effects of a low tidal volume (V (T)) strategy (V (T) a parts per thousand 3 ml/kg/predicted body weight [PBW]) using pumpless extracorporeal lung assist in established ...
Zusammenfassung
Acute respiratory distress syndrome is characterized by damage to the lung caused by various insults, including ventilation itself, and tidal hyperinflation can lead to ventilator induced lung injury (VILI). We investigated the effects of a low tidal volume (V (T)) strategy (V (T) a parts per thousand 3 ml/kg/predicted body weight [PBW]) using pumpless extracorporeal lung assist in established ARDS. Seventy-nine patients were enrolled after a 'stabilization period' (24 h with optimized therapy and high PEEP). They were randomly assigned to receive a low V (T) ventilation (a parts per thousand 3 ml/kg) combined with extracorporeal CO2 elimination, or to a ARDSNet strategy (a parts per thousand 6 ml/kg) without the extracorporeal device. The primary outcome was the 28-days and 60-days ventilator-free days (VFD). Secondary outcome parameters were respiratory mechanics, gas exchange, analgesic/sedation use, complications and hospital mortality. Ventilation with very low V (T)'s was easy to implement with extracorporeal CO2-removal. VFD's within 60 days were not different between the study group (33.2 +/- A 20) and the control group (29.2 +/- A 21, p = 0.469), but in more hypoxemic patients (PaO2/FIO2 a parts per thousand currency sign150) a post hoc analysis demonstrated significant improved VFD-60 in study patients (40.9 +/- A 12.8) compared to control (28.2 +/- A 16.4, p = 0.033). The mortality rate was low (16.5 %) and did not differ between groups. The use of very low V (T) combined with extracorporeal CO2 removal has the potential to further reduce VILI compared with a 'normal' lung protective management. Whether this strategy will improve survival in ARDS patients remains to be determined (Clinical trials NCT 00538928).
Altmetric